PresentationSide effects of aromatase inhibitors versus tamoxifen: the patients’ perspective
References (9)
On the treatment of inoperable cases of carcinoma of the mamma:suggestions for a new method of treatment with illustrative cases
Lancet
(1896)Tamoxifen for early breast cancer: an overview of the randomized trials
Lancet
(1998)- et al.
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Lancet
(2002) - et al.
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
N Engl J Med
(2003)
Cited by (125)
Feasibility of implementing acupuncture in medically underserved breast cancer survivors (FAB): A protocol
2024, Contemporary Clinical TrialsAromatase
2023, Metalloenzymes: From Bench to BedsideLetrozole treatment alters hippocampal gene expression in common marmosets (Callithrix jacchus)
2023, Hormones and BehaviorCitation Excerpt :While AIs are the standard for hormone based adjuvant therapies, they are accompanied by several manifestations of central nervous system (CNS) deficits such as cognitive impairment, insomnia, and hot flashes. These side effects can be severe enough to deter patients from continuing this life-saving treatment (Garreau et al., 2006). Understanding the mechanisms by which AIs induce CNS deficits is critical to finding improved alternatives.
Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients
2020, Gynecologic OncologyCitation Excerpt :Despite the potential clinical efficacy of AIs, their use is associated with a risk of side effects that can be debilitating. These side effects can be broad and diverse, including musculoskeletal symptoms, hot flashes and insomnia [9–12]. The constellation of musculoskeletal symptoms associated with AI therapy has been termed aromatase inhibitor musculoskeletal syndrome (AIMSS) or aromatase inhibitor-related arthralgias (AIA) [13].
Side Effects and Its Management in Adjuvant Endocrine Therapy for Breast Cancer: A Matter of Communication and Counseling
2023, Breast Cancer: Basic and Clinical Research